Bridgebio Pharma Stock Alpha and Beta Analysis
| BBIO Stock | USD 23.42 0.18 0.77% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as BridgeBio Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in BridgeBio Pharma over a specified time horizon. Remember, high BridgeBio Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BridgeBio Pharma's market risk premium analysis include:
Beta 0.94 | Alpha (0.16) | Risk 3.41 | Sharpe Ratio (0.03) | Expected Return (0.1) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
BridgeBio |
BridgeBio Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BridgeBio Pharma market risk premium is the additional return an investor will receive from holding BridgeBio Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BridgeBio Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BridgeBio Pharma's performance over market.| α | -0.16 | β | 0.94 |
BridgeBio Pharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BridgeBio Pharma's Buy-and-hold return. Our buy-and-hold chart shows how BridgeBio Pharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.BridgeBio Pharma Market Price Analysis
Market price analysis indicators help investors to evaluate how BridgeBio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BridgeBio Pharma shares will generate the highest return on investment. By understating and applying BridgeBio Pharma stock market price indicators, traders can identify BridgeBio Pharma position entry and exit signals to maximize returns.
BridgeBio Pharma Return and Market Media
The median price of BridgeBio Pharma for the period between Mon, Aug 26, 2024 and Sun, Nov 24, 2024 is 25.23 with a coefficient of variation of 7.45. The daily time series for the period is distributed with a sample standard deviation of 1.91, arithmetic mean of 25.6, and mean deviation of 1.35. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General Kahn Swick Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO | 08/30/2024 |
2 | BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42 percent Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality a... | 09/27/2024 |
3 | Disposition of 28148 shares by Neil Kumar of BridgeBio Pharma at 24.4 subject to Rule 16b-3 | 10/17/2024 |
4 | BridgeBio Shares Positive Data from High Dose Cohort of Phase 12 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 | 10/24/2024 |
5 | BridgeBio Pharma Expected to Beat Earnings Estimates What to Know Ahead of Q3 Release | 10/31/2024 |
6 | Amphastar Pharmaceuticals Lags Q3 Earnings and Revenue Estimates | 11/06/2024 |
7 | Prosight Management, LP Reduces Stake in Vincerx Pharma Inc | 11/13/2024 |
8 | BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL ... | 11/18/2024 |
9 | BridgeBio Pharmas Acoramidis Shows Competitive Edge Against Pfizers Tafamidisa In Lucrative But Competitive ATTR-CM Market | 11/19/2024 |
10 | Why Is BridgeBio Pharma, Inc. Among the Worst Performing Biotech Stocks in 2024 | 11/21/2024 |
11 | Disposition of 6704 shares by Stephenson Brian C of BridgeBio Pharma subject to Rule 16b-3 | 11/22/2024 |
About BridgeBio Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BridgeBio or other stocks. Alpha measures the amount that position in BridgeBio Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 3.11E-4 | 3.98E-4 | Price To Sales Ratio | 706.43 | 741.75 |
BridgeBio Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of BridgeBio Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BridgeBio Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of BridgeBio Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of BridgeBio Pharma. Please utilize our Beneish M Score to check the likelihood of BridgeBio Pharma's management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with BridgeBio Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out BridgeBio Pharma Backtesting, BridgeBio Pharma Valuation, BridgeBio Pharma Correlation, BridgeBio Pharma Hype Analysis, BridgeBio Pharma Volatility, BridgeBio Pharma History and analyze BridgeBio Pharma Performance. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
BridgeBio Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.